Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 168

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 168
---
 Compensation and Corporate Governance and Nominating Committees, which oversee critical
matters such as our accounting principles, financial reporting practices and system of disclosure controls and internal controls over
financial reporting, our executive compensation program and the selection and evaluation of our directors and director nominees, each
consist entirely of independent directors.

Board Risk Oversight

The Board does not have a standing risk management
committee, but rather administers this oversight function directly through the Board as a whole, as well as through committees of the
Board.

Code of Business Conduct and Ethics

We have adopted a code of business conduct and ethics
for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and
employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at www.mosaicie.com
under the Corporate Governance section of our Investors page. We will promptly disclose on our website (i) the nature of any amendment
to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller,
or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the
policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver.

Insider Trading Policy 

While our Code of Business Conduct and Ethics
strictly prohibits insider trading, we do not maintain insider trading policies and procedures governing the purchase, sale, and/or other
dispositions of our securities by our directors, officers, and employees that we believe are reasonably designed to promote compliance
with insider trading laws, rules, and regulations applicable to us. We have failed to do so due to limited number of directors, officers,
and employees.

Director Legal Proceedings

During the past ten years, no director or executive
officer has been involved in any legal proceedings that are material to an evaluation of their ability or integrity to become our director
or executive officer.

Section 16(a) Beneficial Ownership Reporting Compliance 

Section 16(a) of the Exchange Act requires our directors,
executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the Exchange Act
to file reports of beneficial ownership and changes in beneficial ownership with SEC. Directors, executive officers and greater than 10%
stockholders are required by the rules and regulations of the SEC to furnish us with copies of all reports filed